Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (787)	7/27/2001 11:29:36 PM
From: Biomaven	Read Replies (1) \| Respond to of 1834

Thanks, Miljenko. BTW, Sonata does not have any next day residual effect, none after 4 hr post dosing You are correct - they were actually referring to Ambien & Zopiclone, not Sonata as I had mistakenly recalled. An interesting question is why Sonata hasn't gone with a modified release formula to try to compete with Ambien. In terms of side effects, SEPR claims that S-zopiclone has fewer side effects than Zopiclone, but they haven't given any details lately. Zopiclone does give some small percentage of people a metallic taste in their mouth, and I suspect this may be what SEPR is referring to. The fact that SEPR is considering two dosage levels (a put-you-to-sleep dose and a larger keep-you-asleep dose) suggests to me that it may have an improved therapeutic index over straight Zopiclone. Peter